SkyePharma PLC
News and overview for SkyePharma PLC
SkyePharma: flutiform Phase III study complete - MarketWatch
MarketWatch | 22 days 13 hours 31 minutes ago
SkyePharma: flutiform Phase III study complete
Skyepharma PLC - Board Change [Press Release]
MarketWire | 6 days 11 hours 43 minutes ago
LONDON -- (Marketwire) -- 11/18/09 --
Skyepharma PLC - Interim Management Statement [Press Release]
MarketWire | 12 days 11 hours 43 minutes ago
LONDON -- (Marketwire) -- 11/12/09 --
Flutiform EU Clinical Trial Successfully Completed [Press Release]
MarketWire | 22 days 8 hours 20 minutes ago
LONDON -- (Marketwire) -- 11/02/09 --
Pacira's Phase III Study of EXPAREL(TM) Meets Primary Pain Relief Endpoint [Press Release]
PRNewswire | 35 days 7 hours 43 minutes ago
...is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former SkyePharma PLC injectable business, for which an experienced management team was assembled to address the needs of the acute care...
UPDATE 1-SkyePharma: asthma drug meets goal; EU filing on track
Reuters | 22 days 12 hours 19 minutes ago
Nov 2 (Reuters) - SkyePharma Plc's (SKP.L) asthma drug Flutiform met the main goals in a late-stage trial and the company said it was on track to apply for European regulatory approval in the first quarter of 2010, sending its shares up as much as 22 percent.
GARTMORE FLEDGLING TRUST PLC - Final Results [Press Release]
PRNewswire | 92 days 18 hours 40 minutes ago
GARTMORE FLEDGLING TRUST PLC Final Results for the year to 30 June 2009 The following comprises extracts from the Company's Annual Report & Accounts for the year to 30 June 2009. The full Annual Report and Accounts is available to be viewed or downloaded from the Company's website at http:// www.gartmorefledglingtrust.co.uk . Copies will be mailed to shareholders shortly. ...
7 Results
Sign up for AdvaMed SmartBrief
Company Overview
| Company: | SkyePharma PLC |
|---|---|
| Industry: | Drug Delivery Systems |
| Website: | http://www.skyepharma.com |
There's good karma for aging pharmaceuticals at SkyePharma. The company uses its controlled-release drug delivery technologies for inhaled, oral, and topical drugs to produce more effective versions of already proven therapies. It makes money from partnerships with other pharmaceutical companies, such as GlaxoSmithKline and Sciele Pharma, who seek out SkyePharma's drug delivery expertise. The firm also develops some compounds on its own and then licenses them to others for marketing. Its lead proprietary candidate is Flutiform, an inhaled treatment for asthma and chronic obstructive pulmonary disease (COPD).
Key Numbers
| Sales in U.S. Dollars (mil.) | 90 (2008) |
|---|---|
| One-year % Growth in Sales | 8.4 (2008) |
| Net Income in U.S. Dollars (mil.) | -41.5 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 0 (0) |
| One-year % Growth in Number of Employees | 0.0 (0) |
| Fiscal Year-End | December |